Viewpoints: When Pills Change Appearance, Patients Get Confused; White House Guts Harm Reduction Funding
Opinion writers tackle these public health topics.
The independent source for health policy research, polling, and news.
1 - 20 of 112,219 Results
Opinion writers tackle these public health topics.
Each week, KFF Health News finds longer stories for you to read. Today's selections are on cancer testing, mental health, hantavirus, alcohol treatment, and more.
Officials from the California Office of Environmental Health Hazard Assessment shared data showing the levels of acrolein and ethylene oxide in the ambient air are much stronger than previously thought.
The World Health Organization's annual health statistics report explains that less international aid from wealthy countries has disrupted medical services and weakened disease surveillance. This, along with the lasting impacts of the COVID-19 pandemic, is contributing to many dying of preventable causes, CIDRAP reports.
Most doctors who took the survey say that mandatory prior authorizations have increased over the past five years. Only 1 in 3 say that insurance companies' pledge to smooth the process will make a "meaningful" difference.
“DOJ has proven unworthy of this trust at every point in this case,” U.S. District Judge Mary McElroy wrote in her ruling blocking the administration from getting information from Rhode Island’s largest hospital that provides gender-affirming care to minors. The Department of Justice plans to appeal.
The tally of those being monitored post-exposure is higher than previously thought, MedPage Today reports. Also: An American oncologist who was traveling on the cruise ship and helped care for fellow passengers is cleared to leave a special biocontainment unit in Nebraska, AP reports.
The court intervened at the behest of two manufacturers of mifepristone on Thursday, after the U.S. Court of Appeals for the Fifth Circuit restricted access to the drug nationwide. The order means that the Fifth Circuit’s decision will remain blocked while litigation continues in the lower courts. The issue could eventually return to the high court.
Today's early morning highlights from the major news organizations.
Editorial writers delve into these public health issues.
Each week, KFF Health News compiles a selection of health policy studies and briefs.
New measures signed by Gov. Abigail Spanberger, a Democrat, limit the out-of-pocket cost of insulin to $35 and expand what insurance plans must cover. The laws go into effect July 1. Also: Iowa enacts prior authorization reform; and more.
An analysis of the 2023 National Immunization Survey-Teen found that states in the Northeast census region had significantly higher odds of HPV vaccine uptake, while states in the South had significantly lower odds, CIDRAP reports. The HPV vaccine is credited with lowering the cervical cancer risk by 80% in women vaccinated by age 16 and by 66% in those vaccinated after 16.
Fierce Healthcare reports that nurses feel they have more time with patients and are more accepting of AI in the workplace. Doctors, on the other hand, are more skeptical of new technologies, as they already feel overburdened and lack the time to adjust to the latest technology.
The Wall Street Journal reports that deaths have declined for three years in a row, falling to prepandemic levels, according to preliminary data from the CDC released Wednesday. Also in public health news: alcohol's effect on the body, poisonous wild mushrooms in California, parkour for older adults, and more.
Modern Healthcare reports that the pause is part of the agency's latest effort to address fraud in the healthcare system. Also: CMS rolls out prior authorization plan; news outlets continue their coverage on Marty Makary's exit from the FDA; and more.
The Hill reports on messaging out of the CDC, including that "the risk to the general public is low." Also: why germs spread on cruise ships and how parents can discuss hantavirus with children.
Today's early morning highlights from the major news organizations.
Opinion writers examine these public health issues.
The New York Times reports on daraxonrasib, the first drug to substantially extend the lives of patients with pancreatic cancer. The cellular proteins it targets fuel the three leading causes of cancer deaths: pancreatic tumors, lung, and colon cancers. The drug is fast-tracked for review by the Food and Drug Administration and could win approval later this year.
© 2026 KFF